(Q43281208)

English

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

scientific article published on 2 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

object named as

Timon Bogumil

17

0 references

Massimo Filippi

object named as

Massimo Filippi

M Filippi

2

20

0 references

Hans-Peter Hartung

7

object named as

Hans-Peter Hartung

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

9

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

4

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Bénédicte Dubois

1 reference

ORCID Public Data File 2021

Douglas S Goodin

6

object named as

Douglas Goodin

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Rupert Sandbrink

15

object named as

Rupert Sandbrink

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Christoph Pohling

16

object named as

Christoph Pohl

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Barry G W Arnason

3

object named as

Barry Arnason

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Volker Knappertz

13

object named as

Volker Knappertz

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

BEYOND Study Group

18

object named as

BEYOND Study Group

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

author name string

Paul O'Connor

1

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Stuart Cook

5

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Douglas Jeffery

8

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Francis Boateng

10

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Vitali Filippov

11

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Maria Groth

12

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Christian Kraus

14

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

P O'Connor

19

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

B Arnason

21

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

S Cook

22

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

D Goodin

23

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

H-P Hartung

24

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

L Kappos

25

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

D Jeffery

26

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

G Comi

27

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

publication date

2 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

889-897

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Will Rogers phenomenon in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970226-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(09)70226-1

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

release_tp6tyrk2oraphmaglswc4ygiai

1 reference

https://api.fatcat.wiki/v0/release/tp6tyrk2oraphmaglswc4ygiai

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43281208&oldid=1985540265"